Table 4.

Genotype frequencies of CTLA-4 polymorphisms in breast cancer patients and healthy controls

Genotype		Frequency, no. (%)		P-value	Odds ratio (95% CI)
		Patients (n = 117)	Controls (n = 148)
-1661, G/A#	AA	62 (56.9)	111 (75.0)	0.0022	0.44 (0.26–0.74)
	AG	45 (41.3)	35 (23.7)	0.0025	2.27 (1.33–3.87)
	GG	2 (1.8)	2 (1.4)	0.76
-658, T/C†	CC	109 (94.8)	105 (72.4)	0.0000027	6.92 (3.08–15.52)
	TC	6 (5.2)	40 (27.6)	0.0000027	0.14 (0.06–0.32)
	TT	0	0
-318, T/C	CC	84 (71.8)	129 (87.2)	0.0018	0.37 (0.20–0.69)
	TC	33 (28.2)	19 (12.8)	0.0018	2.67 (1.44–4.93)
	TT	0	0
+49, G/A	AA	48 (41.0)	55 (37.2)	0.52
	AG	59 (50.4)	70 (47.3)	0.61
	GG	10 (8.6)	23 (15.5)	0.090
CT60, G/A	AA	46 (39.3)	74 (50.0)	0.080
	AG	47 (40.2)	56 (37.8)	0.70
	GG	24 (20.5)	18 (12.2)	0.060

^# patients (n = 109), missing (n = 8); controls (n = 148), missing (n = 0)

^† patients (n = 115), missing (n = 2); controls (n = 145), missing (n = 3)